Loading
A phase 2 trial of Pimicotinib in tenosynovial giant cell tumour, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, now recruiting.
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) is a phase 2 interventional study registered as NCT07499362 by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, with 20 participants planned, started 2026-03-26 and due to reach its primary completion in 2029-11-22. Interventions recorded: Pimicotinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Tenosynovial giant cell tumour (TGCT) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Pimicotinib, Tenosynovial giant cell tumour (TGCT), Merck KGaA (EMD Serono).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/